SecBot SecBot

SLXN

Silexion Therapeutics Corp
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. E9· CIK 0002022416 Biotech & Drug Discovery
$0.1750 −0.01 (−7.41%)
Oct 26 4:00 PM ET · prev $0.1890
Market cap
$2.4M
Nano cap
Median target
$5.00
+2757% · range $5.00–5.00
1 year
−99.5%
from $34.70 · Oct 27
30 days
−29.4%
from $0.2480
52-week range
$0.1530–34.70
−99% from high · low Oct 16
Avg volume 20D
14.90M
Sep 29 spike 256.57M
Short interest
🔒 Subscribers only
Insider net
−$31.0K
0 buyers · 1 seller · 12 mo
Filing reports
16
analyzed by SecBot
SecBot read BEARISH 17 reports · 90 days
Balance 12 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 11/17
Strongest BEARISH Silexion Therapeutics adjourned its extraordinary general meeting to October 26, 2026, without conducting…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $31.0K.

  • EstimatesRISING

    Current-quarter EPS estimate −$13.300 → −$0.910 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    43% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Sep 29.

Who's buying

13F
Top holderSharesValue
ROYAL BANK OF CANADA76$0.00
HRT FINANCIAL LP15,239$38.0K
UBS Group AG1,411$3.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Dec 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +2757%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Dec 15, 2025Litchfield Hills
INITIATE
INITIATEBuy
Mar 20, 2025Maxim Group
MAINTAIN
MAINTAINBuy
Nov 1, 2024Maxim Group
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 30, 2026
Announcement
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer
Sep 30, 2026
Short interest
Short Interest: SLXN up 1964% to 4.9M shares
Settlement 2026-09-30 | Days to cover: 1.00 | ≈34.03% of shares outstanding (est.)
Sep 29, 2026
Announcement
Silexion Therapeutics Announces Exercise of Warrants
Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage…
Sep 28, 2026
Announcement
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown
Aug 25, 2026
Listing
Listing Status: SLXN — Deficient (was Normal)
Silexion Therapeutics Corp - Ordinary Shares | Nasdaq Financial Status Indicator N → D

Insider ledger

Form 4
$0
bought · 0 insiders
$31.0K
sold · 1 insider
DateInsiderTypeValue
Jun 4, 2026
Hadar Ilan
Chairman and CEO
AWARD10,000 sh
Jun 4, 2026
Horenshtein Hadar Mirit
CFO and Secretary
AWARD7,500 sh
Jun 4, 2026
Shirvan Mitchell
CSO and CDO
AWARD6,000 sh
Mar 26, 2026
Shirvan Mitchell
CSO and CDO
SELL$31.0K
Feb 20, 2026
Abramov Dror Yosef
Director
AWARD9,091 sh
Feb 20, 2026
Alon Ruth
Director
AWARD9,091 sh
Feb 20, 2026
Shirvan Mitchell
CSO and CDO
AWARD49,726 sh
Feb 20, 2026
Peled Amnon
Director
AWARD7,576 sh

Earnings setup

Estimates
−$0.91
EPS estimate, this quarter
+93%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.91-$0.91–-$0.91+40.1%$0.00
Next Q-$0.71-$0.71–-$0.71+2.7%$0.00
Current FY-$4.84-$4.99–-$4.70+2.9%$0.00
Next FY-$2.02-$2.21–-$1.84+89.1%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
Silexion Therapeutics adjourned its extraordinary general meeting to October 26, 2026, without conducting business…
DEFA14A — Impact 6/10
Oct 5, 2026 SEC
Silexion Therapeutics is holding an extraordinary general meeting on October 19, 2026 to seek shareholder approval for…
DEF 14A — Impact 7/10
Sep 30, 2026 SEC
Silexion Therapeutics announced the first patient has been dosed in its Phase 2/3 clinical trial of SIL204 for locally…
8-K — Impact 6/10
Sep 30, 2026 Press
Silexion Therapeutics dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer…
Impact 7/10
Sep 30, 2026 Announcement
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with l
Sep 29, 2026 Press
Silexion Therapeutics entered into definitive agreements for the immediate cash exercise of outstanding Series E…
Impact 6/10
Jun 4, 2026 Insider
Hadar Ilan was granted 10,000 shares
Chairman and CEO
Jun 4, 2026 Insider
Horenshtein Hadar Mirit was granted 7,500 shares
CFO and Secretary
Reddit
Recent posts
r/pennystocks Neutral 27d ago
29 SEPTEMEBER 2026 , WHAT ARE THE BIGGEST WINNERS AND WHY ?
1 upvotes · 2 comments
All social signals and their track records

SecBot reports

16 filings · 13 press releases · 1 bullish · 9 bearish · 6 neutral
All SLXN filing & press-release reports (29)